1. Home
  2. ALMU vs IKT Comparison

ALMU vs IKT Comparison

Compare ALMU & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeluma Inc.

ALMU

Aeluma Inc.

HOLD

Current Price

$17.60

Market Cap

257.6M

Sector

Technology

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.04

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALMU
IKT
Founded
2019
2008
Country
United States
United States
Employees
14
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
257.6M
220.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ALMU
IKT
Price
$17.60
$2.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$24.67
$5.00
AVG Volume (30 Days)
626.8K
887.2K
Earning Date
05-13-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.49
N/A
Revenue Next Year
$60.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.24
$1.33
52 Week High
$31.79
$2.26

Technical Indicators

Market Signals
Indicator
ALMU
IKT
Relative Strength Index (RSI) 37.45 66.00
Support Level $14.70 $1.59
Resistance Level $17.64 $2.13
Average True Range (ATR) 1.71 0.11
MACD -0.49 0.02
Stochastic Oscillator 8.03 73.53

Price Performance

Historical Comparison
ALMU
IKT

About ALMU Aeluma Inc.

Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: